Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-08, Stock:ABBV, The news for the past five days is as follows:
2018-06-01: NEWS1: After Hours Most Active for Jun 1, 2018 :  ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT.NEWS2: After Hours Most Active for Jun 1, 2018 :  ODP, PRSP, GME, ATUS$, QQQ, OKTA, ABBV, FOXA, GDDY, GM, ZNGA, MSFT.NEWS3: Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone.NEWS4: How Novartis, Insurers Are Taking Wind Out Of AbbVie&apos;s Sales.NEWS5: Solid Month Ends with New Round of Trade Fears.NEWS6: Solid Month Ends with New Round of Trade Fears.NEWS7: Solid Month Ends with New Round of Trade Fears.NEWS8: Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod.NEWS9: Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod.
2018-06-04: NEWS1: Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis.NEWS2: Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis.NEWS3: Today's Research Reports on Trending Tickers: AbbVie and TherapeuticsMD.NEWS4: AbbVie Announces Final Results of Tender Offer.
2018-06-05: NEWS1: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS2: Health Care Select Sector SPDR Fund Experiences Big Inflow.NEWS3: AbbVie's rheumatoid arthritis drug succeeds in late-stage study.NEWS4: AbbVie's rheumatoid arthritis drug succeeds in late-stage study.NEWS5: Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis.
2018-06-06: NEWS1: Gilead Collaborates with Hookipa for HBV and HIV Therapies.NEWS2: Gilead Collaborates with Hookipa for HBV and HIV Therapies.NEWS3: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS4: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS5: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS6: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS7: Abbvie&apos;s (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS8: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS9: 2 Cheap Dividend Stocks You Can Buy Right Now.NEWS10: 2 Cheap Dividend Stocks You Can Buy Right Now.NEWS11: 2 Cheap Dividend Stocks You Can Buy Right Now.
2018-06-07: NEWS1: Should You Stick With Gilead Sciences?.NEWS2: Should You Stick With Gilead Sciences?.NEWS3: [$$] Big Pharma's Tempting Payouts.

Answer: Rise